 "Aurobindo Pharma slips 8% on USFDA warning for Andhra Pradesh facility")
Aurobindo Pharma shares slipped 8 per cent to Rs 579 on the BSE in early morning trade on Friday after the company received a warning letter from US health regulator for its Unit XI, API (Active Pharmaceutical Ingredients) manufacturing facility in Srikakulam, Andhra Pradesh.
The stock was trading close to its 52-week low of Rs 566 touched on July 19, 2018 on the BSE in intra-day trade.
The company said the action follows the earlier inspection of the site by the USFDA (United States Food and Drug Administration) agency in February 2019.
“The Company has received a warning letter dated June 20, 2019 from USFDA relating to our Unit XI, API manufacturing facility situated at Sy.No.61-66, IDA, Pydibhimavaram, Ranasthalam (Mandal), Srikakulam District, Andhra Pradesh,” Aurobindo Pharma said in a regulatory filing.
The company said it believes the existing business from this facility will not be impacted. It will be engaging with the regulator and are fully committed in resolving this issue at the earliest.
The stock has underperformed the market by falling 30 per cent from its recent high of Rs 830 on April 26. In comparison, the S&P BSE Sensex was up 1.4 per cent during the same period.
Aurobindo Pharma’s net debt jumped 43 per cent YoY to Rs 5,008 crore in March 2019. The increase was attributed to two acquisitions – Spectrum in the US and Apotex portfolio in Europe. The increase in working capital on account of higher inventory is intentional (to capture new business opportunities in the US).
“The stock has underperformed market on regulatory concerns related to three API/intermediate plants. We believe the concerns are misplaced as only 5-6 products (out of 100+ pending) are dependent on these plants. With high visibility on FY21E EPS of Rs 53.2 driven by the Sandoz acquisition,” analysts at HDFC Securities said in report dated May 29, 2019.
At 09:56 am, Aurobindo Pharma was trading 6 per cent lower at Rs 588 on the BSE, against a 0.53 per cent decline in the S&P BSE Sensex. The trading volumes on the counter doubled with a combined 2.91 million shares changing hands on the NSE and BSE so far.
The stock was trading close to its 52-week low of Rs 566 touched on July 19, 2018 on the BSE in intra-day trade.
The company said the action follows the earlier inspection of the site by the USFDA (United States Food and Drug Administration) agency in February 2019.
“The Company has received a warning letter dated June 20, 2019 from USFDA relating to our Unit XI, API manufacturing facility situated at Sy.No.61-66, IDA, Pydibhimavaram, Ranasthalam (Mandal), Srikakulam District, Andhra Pradesh,” Aurobindo Pharma said in a regulatory filing.
The company said it believes the existing business from this facility will not be impacted. It will be engaging with the regulator and are fully committed in resolving this issue at the earliest.
The stock has underperformed the market by falling 30 per cent from its recent high of Rs 830 on April 26. In comparison, the S&P BSE Sensex was up 1.4 per cent during the same period.
Aurobindo Pharma’s net debt jumped 43 per cent YoY to Rs 5,008 crore in March 2019. The increase was attributed to two acquisitions – Spectrum in the US and Apotex portfolio in Europe. The increase in working capital on account of higher inventory is intentional (to capture new business opportunities in the US).
“The stock has underperformed market on regulatory concerns related to three API/intermediate plants. We believe the concerns are misplaced as only 5-6 products (out of 100+ pending) are dependent on these plants. With high visibility on FY21E EPS of Rs 53.2 driven by the Sandoz acquisition,” analysts at HDFC Securities said in report dated May 29, 2019.
At 09:56 am, Aurobindo Pharma was trading 6 per cent lower at Rs 588 on the BSE, against a 0.53 per cent decline in the S&P BSE Sensex. The trading volumes on the counter doubled with a combined 2.91 million shares changing hands on the NSE and BSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%